Skip to main content
Premium Trial:

Request an Annual Quote

Emosis, 5-Diagnostics Ink Distribution Deal

The article has been corrected to reflect that Emosis is based in Strasbourg, France. We regret the error. 

NEW YORK (360Dx) – Cytomolecular diagnostics firm Emosis and hemostasis and in vitro diagnostics solutions company 5-Diagnostics announced today an exclusive distribution deal for Emosis' first test.

As part of the deal, which covers at least 36 countries, Emosis has initiated commercialization of its first Emo-test, called HIT Confirm, in countries that recognize the CE mark. HIT Confirm is a blood-based test for confirming the diagnosis of heparin-induced thrombocytopenia. Financial and other terms of the agreement were not disclosed.

Based in Strasbourg, France Emosis calls itself a cell-based hemostasis testing firm. Its Emo-tests are being developed for use with flow cytometers. 5-Diagnostics is headquartered in Basel, Switzerland and specializes in the distribution of hemostasis products.